Milan Scheidegger
Leader of Psychedelic Research at University of Zurich
Key Impact
Investigates how psychedelics enhance neurobehavioral plasticity and support psychotherapy.
Background & Research
Milan Scheidegger leads the Psychedelic Research & Therapy Development group in Zurich. With a background in medicine, neuroscience, and philosophy, he develops novel formulations for DMT and 5-MeO-DMT. His translational research explores how psychedelic-induced plasticity can be harnessed to facilitate healing and transformative experiences in both clinical and naturalistic settings.
Collaboration Network
26 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Healthy VolunteersDepressive DisordersNeuroimaging & Brain MeasuresAnxiety DisordersInterpersonal Functioning & Social ConnectednessSet & SettingPersonality & Trait FactorsSafety & Risk ManagementMedicinal Chemistry & Drug DevelopmentSubstance Use Disorders (SUD)Equity and EthicsCreativityImplementation & Service DeliveryPublic Health, Prevention & Behaviour ChangeChronic PainPTSDBipolar DisorderSchizophreniaMajor Depressive Disorder (MDD)